Bei Akademie registrieren
NTRA, US6323071042

Natera presents 20 ESMO abstracts as Natera stock trades at EUR 360.55

Published on 10/24/2026 at 10:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Natera will present 20 abstracts at ESMO from October 23 to October 26. Natera stock trades at EUR 360.55 in weekend trading on October 24, 2026.

Evidence and scheduled presentations

  • On October 18, Natera announced that 20 abstracts featuring its technology would be presented at ESMO.
  • Natera stock trades in weekend trading at Lang & Schwarz at EUR 360.55 at 10:27 a.m. CEST on October 24, 2026.
  • The ESMO program runs from October 23 through October 26, 2026.
NTRA, US6323071042, Illustration mit AI erstellt.
NTRA, US6323071042, Illustration mit AI erstellt.

Natera announced on October 18, 2026, that 20 abstracts featuring its technology would be presented at the 2026 European Society for Medical Oncology Annual Congress in Madrid from October 23 through October 26. The announcement was made by Natera.

At 10:27 a.m. CEST on October 24, 2026, Natera stock traded in weekend trading at Lang & Schwarz at EUR 360.55. The quote was unchanged from the displayed reference level.

Weekend trading

The Lang & Schwarz price was recorded during the published weekend-trading window. The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Natera stock.

ESMO program

Natera said the program would include four rapid oral presentations. Its release highlighted Signatera Genome with Phased and Structural Variants, which it said had demonstrated a limit of detection below 1 part per million and detection observed significantly below 1 part per 10 million. These details are reported in the company release.

Separately, Natera announced on October 13, 2026, a strategic collaboration with TransCode Therapeutics to support enrollment for a Phase 2a colorectal-cancer trial using Signatera to identify patients who remain positive for molecular residual disease. The announcement is detailed in a Natera release.

Market context: Market report S&P 500.

Upcoming presentations

The release lists presentations on October 24, October 25 and October 26, 2026, including rapid oral and poster sessions covering breast, colorectal, bladder and other cancers.

Disclaimer...
en | US6323071042 | NTRA | boerse | 70403488 | bgmi